Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Survival Outcomes After Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Baseline Tumor Features

  • By

  • Mike Wenzel

  • Quynh Chi Le

  • Carolin Siech

  • Benedikt Hoeh

  • Konrad Klimek

  • Christian Happel

  • Fred Saad

  • Felix Preisser

  • Derya Tilki

  • Markus Graefen

  • Thomas Steuber

  • Tobias Maurer

  • Maximilian C. Kriegmair

  • Pierre I. Karakiewicz

  • Felix K. H. Chun

  • Daniel Groener

  • Philipp Mandel

  • October 20, 2026

Share

  • 1

    This retrospective FRAMCAP study included 344 patients with mCRPC treated with Lu-177-PSMA in treatment lines 1 through 7.

  • 2

    Of the 344 patients, 198 had synchronous and 146 had metachronous metastases at the mHSPC stage.

  • 3

    Median PFS was 12.1 months for synchronous and 13.0 months for metachronous disease, with no significant difference (P = .53).

  • 4

    Median PFS was 12.9 months for Gleason score 6 to 7 and 11.8 months for score 8 to 10, with no significant difference (P = .35).

  • 5

    Median PFS by M stage was 11.9 months for M1a, 9.5 months for M1b, and 8.2 months for M1c disease (P = .08).

Original Source(s)

Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics

  • by Mike Wenzel, Quynh Chi Le, Carolin Siech, Benedikt Hoeh, Konrad Klimek, Christian Happel, Fred Saad, Felix Preisser, Derya Tilki, Markus Graefen, Thomas Steuber, Tobias Maurer, Maximilian C. Kriegmair, Pierre I. Karakiewicz, Felix K. H. Chun, Daniel Groener, Philipp Mandel

  • October 20, 2026

Related Content

Musings From the Power List: Jason Bock

Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development

Musings from The Power List: Piers Ingram

Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines

CEBP-altered B-ALL: Two transcriptomic profiles across the age spectrum